硬骨素
DNA甲基化
甲基化
生物标志物
内科学
骨矿物
医学
内分泌学
癌症研究
生物
基因
骨质疏松症
基因表达
遗传学
Wnt信号通路
作者
Álvaro del Real,Flor M. Pérez-Campo,María Isabel Pérez‐Núñez,Carolina Sañudo,Ana Santurtún,Carmen García‐Ibarbia,María Teresa García‐Unzueta,Mario F. Fraga,Agustín F. Fernández,Carmen Valero,Esther Laguna-Bercero,José A. Riancho
出处
期刊:Genetic Testing and Molecular Biomarkers
[Mary Ann Liebert, Inc.]
日期:2020-12-29
卷期号:25 (1): 42-47
被引量:1
标识
DOI:10.1089/gtmb.2020.0172
摘要
Introduction: Cell-free DNA (cfDNA) methylation is an important molecular biomarker, which provides information about the regulation of gene expression in the tissue of origin. There is an inverse correlation between SOST gene methylation and expression levels. Methods: We analyzed SOST promoter methylation in cfDNA from serum, and compared it with DNA from blood and bone cells from patients undergoing hip replacement surgery. We also measured cfDNA methylation in 28 osteoporotic patients at baseline and after 6 months of antiosteoporotic therapy (alendronate, teriparatide, or denosumab). Results: SOST gene promoter methylation levels in serum cfDNA were very similar to those of bone-derived DNA (79% ± 12% and 82% ± 7%, respectively), but lower than methylation levels in blood cell DNA (87% ± 10%). Furthermore, there was a positive correlation between an individual's SOST DNA methylation values in serum and bone. No differences in either serum sclerostin levels or SOST methylation were found after 6-months of therapy with antiosteoporotic drugs. Conclusions: Our results suggest that serum cfDNA does not originate from blood cells, but rather from bone. However, since we did not confirm changes in this marker after therapy with bone-active drugs, further studies examining the correlation between bone changes of SOST expression and SOST methylation in cfDNA are needed to confirm its potential role as a bone biomarker.
科研通智能强力驱动
Strongly Powered by AbleSci AI